References
- Cawthorne M. A., Lister C. A., Holder J. C., Kirkham D. M., Young P. W., Cantello B. C., Hindley R. M., Smith S. A. Anti-hyperglycaemic efficacy of a highly potent thiazolidinedione in animal models of non-insulin dependent diabetes. Diabetes 1993; 42(suppl. 1)204A
- Doi T., Tsukamoto T., Torii H., Yoshida K., Tanayama S. Metabolism and disposition of 5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione (CT-112), a new aldose reductase inhibitor, in rats and dogs. Journal of the Takeda Research Laboratory 1984; 43: 19–32
- Fouda H. G., Lukaszewicz J., Clarke D. A., Hulin B. Metabolism of a new thiazolidinedione hypoglycemic agent CP-68,722 in rat: metabolite identification by gas chromatography mass spectrometry. Xenobiotica 1991; 21: 925–934
- Ibrahimi A., Teboul L., Gaillard D., Amri E., Ailhaud G., Young P., Cawthorne M. A., Grimaldi P. A. Evidence for a common mechanism of action for fatty acids and thiazolidinediones antidiabetic agents on gene expression in preadipose cells. Molecular Pharmacology 1994; 46: 1070–1076
- Krieter P. A., Colletti A. E., Doss D. A., Miller R. R. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metabolism and Disposition 1994; 22: 625–630
- Tomlinson P. W., Jeffery D. J., Filer C. W. A novel technique for assessment of biliary secretion and enterohepatic circulation in the unrestrained conscious rat. Xenobiotica 1981; 11: 863–870
- Torii H., Yoshida K., Tsukamoto T., Tanayama S. Disposition in rats and dogs of ciglitazone, a new antidiabetic agent. Xenobiotica 1984; 14: 259–268
- Yoshida K., Torii H., Sugiyama Y., Fujita T., Tanayama S. Rat plasma metabolites of ciglitazone, a new antidiabetic agent. Xenobiotica 1984; 14: 249–257